TY  - GEN
AU  - Furusyo,Norihiro
AU  - Kajiwara,Eiji
AU  - Takahashi,Kazuhiro
AU  - Nomura,Hideyuki
AU  - Tanabe,Yuichi
AU  - Masumoto,Akihide
AU  - Maruyama,Toshihiro
AU  - Nakamuta,Makoto
AU  - Enjoji,Munechika
AU  - Azuma,Koichi
AU  - Shimono,Junya
AU  - Sakai,Hironori
AU  - Shimoda,Shinji
AU  - Hayashi,Jun
TI  - Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group
SN  - 1440-1746
PY  - 2008///1030
KW  - Adult
KW  - Aged
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Asian People
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C, Chronic
KW  - diagnosis
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Japan
KW  - Male
KW  - Middle Aged
KW  - Polyethylene Glycols
KW  - Prospective Studies
KW  - RNA, Viral
KW  - blood
KW  - Recombinant Proteins
KW  - Ribavirin
KW  - Time Factors
KW  - Treatment Outcome
KW  - Viral Load
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study
UR  - https://doi.org/10.1111/j.1440-1746.2008.05319.x
ER  -